AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7378674 — intervention group
Group type: EXPERIMENTAL
Intervention: Iotroxamide infusion at an optimal rate of around 4 mg/kg/min
Number of subjects: 24
Study 7378674 — intervention group
Group type: EXPERIMENTAL
Intervention: Iotroxamide infusion
Number of subjects: 24
Study 30232538 — intervention group
Group type: COMPARATOR
Intervention: Multi-faceted patient and physician educational intervention (active control arm)
Number of subjects: 131
Study 30232538 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led case manager (study arm)
Number of subjects: 131
Study 27828786 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetanic stimulation (group T)
Number of subjects: 50
Study 27828786 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 50
Study 26269566 — intervention group
Group type: EXPERIMENTAL
Intervention: l-alanyl-l-glutamine (8 g/d) and polyunsaturated fatty acid (6.5 g/d)
Number of subjects: 31
Study 26269566 — intervention group
Group type: COMPARATOR
Intervention: Placebo (safflower oil and milk powder)
Number of subjects: 31
Study 24223963 — intervention group
Group type: EXPERIMENTAL
Intervention: Forward digit recall
Number of subjects: 37
Study 24223963 — intervention group
Group type: EXPERIMENTAL
Intervention: Backward digit recall
Number of subjects: 37
Study 24223963 — intervention group
Group type: EXPERIMENTAL
Intervention: Forward letter recall
Number of subjects: 37
Study 24223963 — intervention group
Group type: EXPERIMENTAL
Intervention: Backward letter recall
Number of subjects: 37
Study 24223963 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal short-term memory
Number of subjects: 37
Study 24223963 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal working memory
Number of subjects: 37
Study 22109783 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity program for preschool children, including structured activities and professional development for staff.
Number of subjects: 0
Study 22109783 — intervention group
Group type: COMPARATOR
Intervention: Usual care activities (control group)
Number of subjects: 0
Study 19856790 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of cetirizine hydrochloride
Number of subjects: 18
Study 19856790 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of cetirizine hydrochloride
Number of subjects: 18
Study 17572834 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot stamping, progressively loaded squats, and in‐line dancing
Number of subjects: 45
Study 14747227 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldose reductase inhibitor (ARI) zopolrestat 500 or 1,000 mg daily for 1 year
Number of subjects: 81
Study 14747227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 11154482 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical pharyngeal anesthesia
Number of subjects: 201
Study 11154482 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 9663180 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/day oral fluconazole
Number of subjects: 25
Study 9663180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 9663180 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole and Placebo
Number of subjects: 25
Study 9663180 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 25
Study 8142663 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir
Number of subjects: 47
Study 8142663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 8142663 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Ganciclovir and Placebo
Number of subjects: 47
Study 3146891 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranylcypromine
Number of subjects: 47
Study 3146891 — intervention group
Group type: COMPARATOR
Intervention: L-5-hydroxytryptophan (L-5HTP)
Number of subjects: 47
Study 3146891 — intervention group
Group type: COMPARATOR
Intervention: Nomifensine
Number of subjects: 47
Study 31770784 — intervention group
Group type: EXPERIMENTAL
Intervention: Poractant alfa
Number of subjects: 73
Study 31770784 — intervention group
Group type: COMPARATOR
Intervention: Beractant
Number of subjects: 73
Study 31539064 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal history of chorioamnionitis
Number of subjects: 105
Study 31539064 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV status
Number of subjects: 105
Study 31539064 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged rupture of membrane
Number of subjects: 105
Study 31539064 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple digital vaginal examinations during labor
Number of subjects: 105
Study 31539064 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal history of perinatal asphyxia
Number of subjects: 105
Study 31093954 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Neurotensin (NTS)
Number of subjects: 165
Study 31093954 — intervention group
Group type: EXPERIMENTAL
Intervention: Loge (plasma NTS concentration)
Number of subjects: 165
Study 31093954 — intervention group
Group type: EXPERIMENTAL
Intervention: Loge (Age)
Number of subjects: 165
Study 31093954 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 165
Study 28777984 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbid nightmare disorder
Number of subjects: 379
Study 28777984 — intervention group
Group type: COMPARATOR
Intervention: No comorbid nightmare disorder
Number of subjects: 379
Study 28777984 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbid sleep terror disorder
Number of subjects: 379
Study 28777984 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbid sleepwalking disorder
Number of subjects: 379
Study 25421472 — intervention group
Group type: EXPERIMENTAL
Intervention: Tedizolid 200 mg once daily for 6 days
Number of subjects: 1333
Study 25421472 — intervention group
Group type: COMPARATOR
Intervention: Linezolid 600 mg twice daily for 10 days
Number of subjects: 1333
Study 25421472 — intervention group
Group type: EXPERIMENTAL
Intervention: Tedizolid
Number of subjects: 1333
Study 25421472 — intervention group
Group type: COMPARATOR
Intervention: Linezolid
Number of subjects: 1333
Study 24078554 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil 1 mg·kg(‐1)
Number of subjects: 62
Study 24078554 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 62
Study 21595951 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by surgery (CS group)
Number of subjects: 169
Study 21595951 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (S group)
Number of subjects: 169
Study 19673614 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg twice daily for 4 days
Number of subjects: 140
Study 19673614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 16275011 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted analysis with prespecified covariate
Number of subjects: 0
Study 16275011 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted analysis with significant predictive strategy
Number of subjects: 0
Study 16275011 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted analysis with significant imbalance strategy
Number of subjects: 0
Study 16275011 — intervention group
Group type: COMPARATOR
Intervention: Unadjusted analysis
Number of subjects: 0
Study 16275011 — intervention group
Group type: EXPERIMENTAL
Intervention: Covariate HR between 2 and 5
Number of subjects: 0
Study 29932413 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5-mg DuvieTM tablets (test drug)
Number of subjects: 28
Study 29932413 — intervention group
Group type: COMPARATOR
Intervention: 0.5-mg DuvieTM tablets (reference drug)
Number of subjects: 28
Study 29932413 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 28
Study 10619929 — intervention group
Group type: EXPERIMENTAL
Intervention: Duraflo II heparin-coated cardiopulmonary bypass circuits
Number of subjects: 24
Study 10619929 — intervention group
Group type: COMPARATOR
Intervention: Noncoated equipment (control group)
Number of subjects: 24
Study 8616766 — intervention group
Group type: EXPERIMENTAL
Intervention: CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin)
Number of subjects: 253
Study 8616766 — intervention group
Group type: COMPARATOR
Intervention: melphalan
Number of subjects: 253
Study 8616766 — intervention group
Group type: EXPERIMENTAL
Intervention: CHAD
Number of subjects: 253
Study 1826237 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of unmodified insulin (10 U)
Number of subjects: 8
Study 1826237 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of unmodified insulin (10 U)
Number of subjects: 8
Study 1826237 — intervention group
Group type: COMPARATOR
Intervention: Hypoglycaemia
Number of subjects: 8
Study 7122669 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg valerian extract
Number of subjects: 128
Study 7122669 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprietary valerian-containing preparation
Number of subjects: 128
Study 7122669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 29528962 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 session·wk per muscle group (G1, n = 10)
Number of subjects: 20
Study 29528962 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 sessions·wk per muscle group (G2, n = 10)
Number of subjects: 20
Study 30241510 — intervention group
Group type: EXPERIMENTAL
Intervention: CYD‐TDV standard 0‐6‐12 months schedule
Number of subjects: 390
Study 30241510 — intervention group
Group type: EXPERIMENTAL
Intervention: CYD‐TDV accelerated 0‐2‐6 months schedule
Number of subjects: 390
Study 30241510 — intervention group
Group type: EXPERIMENTAL
Intervention: CYD‐TDV accelerated schedule with YF co‐administered
Number of subjects: 390
Study 30241510 — intervention group
Group type: COMPARATOR
Intervention: YF vaccination only
Number of subjects: 390
Study 27662279 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 119
Study 27662279 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 119
Study 27662279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 24576515 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen 6 L/min delivered by Oxymask for 6 to 12 hours
Number of subjects: 6600
Study 24576515 — intervention group
Group type: COMPARATOR
Intervention: Room air
Number of subjects: 6600
Study 22569622 — intervention group
Group type: EXPERIMENTAL
Intervention: ETT intracuff 2% lidocaine plus 8.4% sodium bicarbonate (L group)
Number of subjects: 50
Study 22569622 — intervention group
Group type: COMPARATOR
Intervention: ETT intracuff 0.9% saline (S group)
Number of subjects: 50
Study 20385439 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-tricalcium phosphate sinus floor graft with simultaneous implant insertion
Number of subjects: 62
Study 20385439 — intervention group
Group type: COMPARATOR
Intervention: Posterior maxilla implants without sinus lift
Number of subjects: 62
Study 19238877 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (0.4 mg/day) starting at least one month before conception and continuing for the first quarter of pregnancy
Number of subjects: 0
Study 19238877 — intervention group
Group type: COMPARATOR
Intervention: Food fortification strategies
Number of subjects: 0
Study 19238877 — intervention group
Group type: COMPARATOR
Intervention: Promotion of healthy dietary habits
Number of subjects: 0
Study 15989166 — intervention group
Group type: EXPERIMENTAL
Intervention: Various interventions aimed at increasing physical activity and lowering dietary fat; specific dosages and durations not available.
Number of subjects: 30
Study 12024134 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 80
Study 12024134 — intervention group
Group type: COMPARATOR
Intervention: Midazolam plus meperidine
Number of subjects: 80
Study 10509552 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril and HCTZ with nabumetone
Number of subjects: 17
Study 10509552 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril and HCTZ with sulindac
Number of subjects: 17
Study 10509552 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril and HCTZ with ibuprofen
Number of subjects: 17
Study 10509552 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen (washout period)
Number of subjects: 17
Study 7815656 — intervention group
Group type: EXPERIMENTAL
Intervention: Zalcitabine at 0.75 mg every 8 hours
Number of subjects: 338
Study 7815656 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine at 200 mg (later 100 mg) every 4 hours
Number of subjects: 338
Study 1901808 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg ponalrestat
Number of subjects: 54
Study 1901808 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg ponalrestat
Number of subjects: 54
Study 1901808 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 7179208 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin (s.c.) administered as two daily injections
Number of subjects: 141
Study 7179208 — intervention group
Group type: COMPARATOR
Intervention: Continuous intravenous infusion of heparin (i.v.)
Number of subjects: 141
Study 7179208 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin (s.c.)
Number of subjects: 141
Study 31761539 — intervention group
Group type: EXPERIMENTAL
Intervention: LHe 5.6 M
Number of subjects: 0
Study 31761539 — intervention group
Group type: EXPERIMENTAL
Intervention: LHe 6.6 M
Number of subjects: 0
Study 31761539 — intervention group
Group type: EXPERIMENTAL
Intervention: LN 5.6 M
Number of subjects: 0
Study 31761539 — intervention group
Group type: EXPERIMENTAL
Intervention: LN 6.6 M
Number of subjects: 0
Study 31761539 — intervention group
Group type: COMPARATOR
Intervention: Fresh oocytes
Number of subjects: 0
Study 29165558 — intervention group
Group type: EXPERIMENTAL
Intervention: Paro (robotic seal)
Number of subjects: 20
Study 29165558 — intervention group
Group type: COMPARATOR
Intervention: Plush Toy (non-robotic)
Number of subjects: 20
Study 28353579 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (IIT)
Number of subjects: 88
Study 28353579 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin therapy (CIT)
Number of subjects: 88
Study 26890736 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg twice a day
Number of subjects: 80
Study 26890736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 26890736 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 500 mg/day
Number of subjects: 80
Study 26890736 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg/day
Number of subjects: 80
Study 26890736 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1500 mg/day
Number of subjects: 80
Study 26890736 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin maximum dose
Number of subjects: 80
Study 26890736 — intervention group
Group type: COMPARATOR
Intervention: Metformin and Placebo
Number of subjects: 80
Study 25243773 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-mechanism model for decision making based on parallel constraint satisfaction processes (PCS-DM)
Number of subjects: 0
Study 25243773 — intervention group
Group type: COMPARATOR
Intervention: Multi-strategy account
Number of subjects: 0
Study 22906808 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-experience multidisciplinary lifestyle intervention
Number of subjects: 77
Study 21149923 — intervention group
Group type: EXPERIMENTAL
Intervention: DRV/r 800/100 mg once daily
Number of subjects: 689
Study 21149923 — intervention group
Group type: COMPARATOR
Intervention: LPV/r 800/200 mg total daily dose
Number of subjects: 689
Study 17284514 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 90-100 mg kg(‐1) day(‐1)
Number of subjects: 54
Study 17284514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 16084880 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose hCG (200 IU/day) alone after ovarian priming with recombinant FSH/hMG (group B)
Number of subjects: 0
Study 12126926 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentaspan (500 ml, infusion condition)
Number of subjects: 12
Study 12126926 — intervention group
Group type: COMPARATOR
Intervention: Placebo (60 ml saline, non-infusion condition)
Number of subjects: 12
Study 10402256 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual imagery of letters
Number of subjects: 10
Study 10402256 — intervention group
Group type: COMPARATOR
Intervention: Detection of intervening tones
Number of subjects: 10
Study 1414961 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.25‐MJ/d liquid diet supplemented with pyruvate (PY; n = 7)
Number of subjects: 14
Study 1414961 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 7)
Number of subjects: 14
Study 1414961 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PY and placebo)
Number of subjects: 14
Study 3887551 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone (20 mg)
Number of subjects: 10
Study 3887551 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30466714 — intervention group
Group type: EXPERIMENTAL
Intervention: HRV biofeedback
Number of subjects: 78
Study 30466714 — intervention group
Group type: EXPERIMENTAL
Intervention: HRV biofeedback + autogenic training
Number of subjects: 78
Study 30466714 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 78
Study 30672192 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional drug therapy combined with acupuncture (Baihui, Sishencong, Neiguan, Hegu, Taixi), treatment given once daily, 6 times a week for 4 weeks.
Number of subjects: 60
Study 30672192 — intervention group
Group type: COMPARATOR
Intervention: Conventional drug therapy only, treatment given once daily, 6 times a week for 4 weeks.
Number of subjects: 60
Study 27129849 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive training intervention comprising 8 supervised group sessions and home exercises (2/week over 11 weeks)
Number of subjects: 1400
Study 27129849 — intervention group
Group type: COMPARATOR
Intervention: Control group (ratio 10:1 control vs. intervention)
Number of subjects: 1400
Study 26443290 — intervention group
Group type: EXPERIMENTAL
Intervention: IDegLira
Number of subjects: 260
Study 24251308 — intervention group
Group type: EXPERIMENTAL
Intervention: RVOT lead position
Number of subjects: 132
Study 24251308 — intervention group
Group type: COMPARATOR
Intervention: RVA lead position
Number of subjects: 132
Study 21472645 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medicine (CM)
Number of subjects: 0
Study 18307628 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial-based pacing mode (VDD or DDD)
Number of subjects: 12
Study 18307628 — intervention group
Group type: COMPARATOR
Intervention: Ventricular demand pacing mode (VVI)
Number of subjects: 12
Study 18307628 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin-mediated vasodilation
Number of subjects: 12
Study 16540869 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtotal discectomy
Number of subjects: 30
Study 16540869 — intervention group
Group type: COMPARATOR
Intervention: Limited discectomy
Number of subjects: 30
Study 20217660 — intervention group
Group type: EXPERIMENTAL
Intervention: RNP clinic
Number of subjects: 80
Study 20217660 — intervention group
Group type: COMPARATOR
Intervention: JHD clinic
Number of subjects: 80
Study 10634364 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone administration
Number of subjects: 62
Study 10634364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 9447898 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 112
Study 9447898 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin-clavulanic acid
Number of subjects: 112
Study 8182195 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin composite inlays
Number of subjects: 240
Study 8182195 — intervention group
Group type: COMPARATOR
Intervention: Amalgam restorations
Number of subjects: 240
Study 2906699 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil 15-60 mg twice a day for 8 weeks or more
Number of subjects: 129
Study 2906699 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil 15-60 mg twice a day for 1 year or more (monotherapy)
Number of subjects: 129
Study 2906699 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil 15-60 mg twice a day for 1 year or more (combined therapy with thiazide)
Number of subjects: 129
Study 2906699 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil (both monotherapy and combined therapy)
Number of subjects: 129
Study 29274840 — intervention group
Group type: EXPERIMENTAL
Intervention: closed-NPWT
Number of subjects: 49
Study 29274840 — intervention group
Group type: COMPARATOR
Intervention: open-NPWT
Number of subjects: 49
Study 28641703 — intervention group
Group type: COMPARATOR
Intervention: Minimum follow-up (n=301)
Number of subjects: 1202
Study 28641703 — intervention group
Group type: EXPERIMENTAL
Intervention: CEA testing only (n=300)
Number of subjects: 1202
Study 28641703 — intervention group
Group type: EXPERIMENTAL
Intervention: CT only (n=299)
Number of subjects: 1202
Study 28641703 — intervention group
Group type: EXPERIMENTAL
Intervention: CEA testing and CT (n=302)
Number of subjects: 1202
Study 28641703 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (intensive follow-up arms)
Number of subjects: 1202
Study 28641703 — intervention group
Group type: COMPARATOR
Intervention: Overall (minimum follow-up)
Number of subjects: 1202
Study 28641703 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival analysis
Number of subjects: 1202
Study 28641703 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of CEA testing
Number of subjects: 1202
Study 28641703 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of CT
Number of subjects: 1202
Study 28641703 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of CEA testing and CT
Number of subjects: 1202
Study 25335247 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency electric stimulation at acupoints (Dazhui (GV 14) and Shenshu (BL 23)), once a day for 15 days, 2 sessions total.
Number of subjects: 120
Study 25335247 — intervention group
Group type: EXPERIMENTAL
Intervention: Estazolam, 1 mg orally before sleep for 15 days, 2 sessions total.
Number of subjects: 120